Staples’ best known tagline is “Yeah, we’ve got that.” This week, that might have been truer than ever with news...
Fujifilm stated that although revenue and operating income were down due to the impact of the COVID-19 pandemic, the pace of decline is shrinking, with a path to recovery evident in the second quarter.
The firm also provided updates on its development of a COVID-19 treatment and vaccine.
With many office workers working at home, the most vulnerable office-imaging companies are those with a deep presence in office-enterprise A3 copier/MFPs.
The goal of Icahn and Deason isn’t to create the world’s largest copier/printer company, but instead appears to drive the Xerox share price to $40 and then sell.
Fujifilm will focus on its healthcare business, as its copier business is said to slow. But its Chairman and CEO Shigetaka Komori still has Xerox on his mind.
“Therefore, your expectation – as expressed to the Japanese media – that Xerox will come to Fujifilm with a new proposal for a combination transaction is simply delusional.”
Bloomberg also reported that Fujifilm COO Sukeno said that wants to explain to Xerox shareholders that the merger with Fuji Xerox is the only option for Xerox to grow and have a future. A combined entity would be more efficient, he said.
On Wednesday, Xerox also said that Xerox shareholders should disregard information from Icahn and Deason, stating the two are conducting a “highly disingenuous campaign” that distorts and omits key facts about Xerox and the proposed merger.
Icahn and Deason determined to prevent sale of Xerox.